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OBJECTIVE—Glycogen synthase kinase (GSK)-3 plays an
important role in cardiomyopathies. Cardiac-speciﬁc metallo-
thionein-overexpressing transgenic (MT-TG) mice were highly
resistant to diabetes-induced cardiomyopathy. Therefore, we
investigated whether metallothionein cardiac protection against
diabetes is mediated by inactivation of GSK-3.
RESEARCH DESIGN AND METHODS—Diabetes was in-
duced with streptozotocin in both MT-TG and wild-type mice.
Changes of energy metabolism–related molecules, lipid accumu-
lation, inﬂammation, nitrosative damage, and ﬁbrotic remodeling
were examined in the hearts of diabetic mice 2 weeks, 2 months,
and 5 months after the onset of diabetes with Western blotting,
RT-PCR, and immunohistochemical assays.
RESULTS—Activation (dephosphorylation) of GSK-3 was evi-
denced in the hearts of wild-type diabetic mice but not MT-TG
diabetic mice. Correspondingly, cardiac glycogen synthase phos-
phorylation, hexokinase II, PPAR, and PGC-1 expression,
which mediate glucose and lipid metabolisms, were signiﬁcantly
changed along with cardiac lipid accumulation, inﬂammation
(TNF-, plasminogen activator inhibitor 1 [PAI-1], and intracel-
lular adhesion molecule 1 [ICAM-1]), nitrosative damage (3-
nitrotyrosin accumulation), and ﬁbrosis in the wild-type diabetic
mice. The above pathological changes were completely pre-
vented either by cardiac metallothionein in the MT-TG diabetic
mice or by inhibition of GSK-3 activity in the wild-type diabetic
mice with a GSK-3–speciﬁc inhibitor.
CONCLUSIONS—These results suggest that activation of
GSK-3 plays a critical role in diabetes-related changes in cardiac
energy metabolism, inﬂammation, nitrosative damage, and re-
modeling. Metallothionein inactivation of GSK-3 plays a critical
role in preventing diabetic cardiomyopathy. Diabetes 58:1391–
1402, 2009
M
etallothionein, a potent antioxidant, protects
against diabetic cardiomyopathy (1–5). How-
ever, the mechanisms by which metallothio-
nein protects the heart from diabetes are
largely unknown (6). The diabetic heart is characterized
by diminished glucose utilization and increased fatty acid
oxidation, usually resulting in cardiac lipid accumulation
(7,8). The lipotoxicity may be a major trigger for cardiac
inﬂammation and oxidative damage and, eventually, car-
diac dysfunction (7,8).
For glucose metabolism, insulin via its receptor initiates
phosphorylation of insulin receptor intracellular sub-
strates. Insulin receptor substrate family members serve
as docking proteins for downstream signaling molecules,
one of which is phosphatidylinositol (PI) 3-kinase. Activa-
tion of PI 3-kinase and its downstream protein kinase B
(Akt) is essential for almost all insulin-induced glucose
and fatty acid or lipid metabolism such as glucose uptake,
glycogen synthesis, and suppression of triglyceride synthesis
(9). GLUT4 and hexokinase II (HK II) both play critical roles
in glucose transport and phosphorylation to glucose 6-phos-
phate for further glycolysis. HK II was found to be negatively
regulated by glycogen synthase kinase (GSK)-3 (10).
GSK-3 is a ubiquitously expressed serine/threonine ki-
nase that has versatile biological functions in cells, includ-
ing regulation of metabolism, cell growth/death, and gene
transcription and translation (9). Although both GSK-3
and GSK-3 appear to be equally important in certain
aspects, GSK-3 has a more critical role than GSK-3 in
regulating hepatic glucose metabolism and insulin sensi-
tivity, and GSK-3 is the predominant regulator of glyco-
gen synthase in skeletal muscle including the heart
(9,11,12). Unlike most protein kinases, GSK-3 remains
active in its dephosphorylated form and is inactivated
upon phosphorylation by other protein kinases, such as
Akt. In response to insulin, therefore, activated Akt inhib-
its the activity of GSK-3 or GSK-3 isoforms by phosphor-
ylating their NH2-terminal serine residues (Ser21 in
GSK-3 and Ser9 in GSK-3), releasing their inhibitory
effects on glycogen synthase. Dephosphorylated glycogen
synthase and phosphorylated glycogen synthase (Ser641)
are active and inactive forms, respectively, in glycogen
synthesis (9). In diabetes, GSK-3 was activated by de-
creasing its phosphorylation (13,14). In contrast, inactiva-
tion of GSK-3, either by increased Akt phosphorylation
(13,14) or by cardiac-speciﬁc overexpression of dominant
negative GSK-3 (11,15), increased cardiac glucose utili-
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DIABETES, VOL. 58, JUNE 2009 1391zation and lipid metabolism. These studies thus suggest
that GSK-3 phosphorylation plays a critical role in car-
diac glucose metabolism.
In addition, glucose and lipid metabolism in the heart
also are transcriptionally regulated by the peroxisome
proliferator–activated receptor (PPAR) family (PPAR,
-/, and -) of ligand-activated transcription factors.
Both PPAR and PPAR play critical roles in the heart
in regulating glucose and fatty acid metabolisms, while
PPAR is a major regulator of lipid storage in the
adipose tissue where it regulates the differentiation of
adipocytes by sensing lipid availability and adapting appro-
priate gene expression programs (7,8,16). The cardiomyo-
pathic remodeling that occurred in diabetic mice was
accompanied by striking lipid and reactive oxygen species
accumulation in the heart, suggesting a lipotoxic contribu-
tion to cardiomyopathy (7,8,16). Peroxisome proliferator–
activated  coactivator (PGC)-1 is essential for the main-
tenance of maximal, efﬁcient cardiac mitochondrial fatty acid
oxidation, ATP synthesis, and myocardial lipid homeostasis
(17).
The present study, therefore, tested our hypothesis that
GSK-3 activation plays a critical role in diabetes-induced
imbalance in glucose/lipid metabolism, leading to lipid
accumulation that, in turn, evokes cardiac inﬂammation
and oxidative stress/damage and, eventually, cardiac re-
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FIG. 1. Diabetic hyperglycemia and activation of GSK-3. Before mice were killed at the indicated times, blood glucose was monitored at indicated
times, using tail-vein blood (A), and cardiac tissues were used for Western blotting analysis of total and phosphorylated GSK-3 (B). *P < 0.05 vs.
corresponding controls. Ms, months; Ws, weeks; WT, wild type.
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whether and how metallothionein prevents diabetic acti-
vation of GSK-3–mediated pathogenesis.
RESEARCH DESIGN AND METHODS
Diabetes models. Metallothionein-overexpressing transgenic (MT-TG) mice
were produced from the FVB mice that have been well characterized (2,18).
Both 8- to 10-week-old MT-TG positive mice (heterozygotes) and negative
littermates (wild type) were kept in the same cages with free access to rodent
chow and tap water. All animal procedures were approved by the Institutional
Animal Care and Use Committee, which is certiﬁed by the American Associ-
ation for Accreditation of Laboratory Animal Care. Streptozotocin (STZ)
(Sigma, St. Louis, MO) was dissolved in sodium citrate buffer (pH 4.5). Male
mice were given an intraperitoneal injection of STZ at 40 mg/kg body wt daily
for 5 days. Whole-blood glucose obtained from the mouse tail vein was
detected using a SureStep complete blood glucose monitor (LifeScan, Milpi-
tas, CA) 5 days after the last STZ injection. STZ-injected mice with glucose
levels 12 mmol/l were considered diabetic, and mice serving as controls
were given the same volume of sodium citrate (2,4).
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FIG. 2. Diabetes-induced glycogen synthase (GS) phosphorylation and decrease of HK II expression. Cardiac tissues were collected, as indicated
in Fig. 1, for detecting total and phosphorylated glycogen synthase (Ser641) (A) and HK II expression (B) by Western blotting. *P < 0.05 vs.
control. Ms, months; Ws, weeks; WT, wild type.
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after the last STZ injection, were randomly divided into two groups (n  6 for
each), diabetic control and diabetes/inhibitor, to receive SB216763 (Tocris,
Ellisville, MO), a selective inhibitor of GSK-3. SB216763 was given by tail
intravenous injection at 600 g/kg body wt every 2 days for 2 months. Chronic
injection with SB216763 to inhibit GSK-3 has not previously been reported;
however, acute doses of SB216763 with 600 g/kg for mice have been docu-
mented (19). Therefore, we selected this dose of SB216763 given every other day
to avoid excess side effects and keep concentration at a high level. SB216763
injection for 2 months was selected because we found that diabetic mice 2
months after the onset of diabetes started to show cardiac dysfunction (20).
Cell cultures for in vitro experiments. Embryonic rat heart–derived cells
(H9c2) were cultured as previously described (21). H9c2 cells (American Type
Culture Collection CLR-1446; Rockville, MD) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% FBS from Atlanta
Biologicals (Norcross, GA). When cell populations reached 60–70% conﬂu-
ence, the cultures were exposed to ﬂavone acetic acid or tumor necrosis
factor- (TNF-) in a ﬁnal concentration of 50 mol/l or 1.0 ng/ml in cultures
for 24 h. The monolayer cultures were then washed with PBS, and the cells
were harvested by trypsinization for measurements of mRNA expression of
TNF- and plasminogen activator inhibitor 1 (PAI-1), examined by RT-PCR
assay or triglyceride contents by biochemical assay.
Oil Red O staining for lipid accumulation. Cryosections of heart (10-m
thick) were ﬁxed in 10% buffered formalin for 5 min at room temperature,
stained with Oil Red O for 10 min, washed, and then counterstained with
hematoxylin (DAKO, Carpinteria, CA) for 45 s. A Nikon microscope (Nikon,
Melville, NY) was used to capture the Oil Red O–stained tissue sections at
400 magniﬁcation.
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FIG. 3. Diabetes-increased PPAR expression and lipid accumulation. Cardiac tissues were collected, as indicated in Fig. 1, for detecting PPAR
(A) and PGC-1 (B) expressions by Western blotting and cardiac lipid accumulation by Oil Red O staining (400)( C) and triglyceride
measurement (D). Panel D presents the data only from diabetic mice 2 weeks (Ws) after diabetes. *P < 0.05 vs. control; #P < 0.05 vs. wild-type
(WT) diabetic group. Ms, months. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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tissues or cardiac H9C2 cells using Trizol reagent (RNA STAT 60 Tel-Test;
Ambion, Austin, TX). RNA concentrations were determined spectrophoto-
metrically, and 1 g total RNA was reversely transcribed using an avian
myeloblastosis virus reverse-transcriptase kit (Promega, Madison, WI). PCR
primers were designed using PAI-1, TNF-, and intracellular adhesion mole-
cule 1 (ICAM-1) (Applied Biosystems, Foster City, CA). Primers were designed
to cross introns to ensure that only cDNA, not DNA, was ampliﬁed. TaqMan
Universal PCR Master Mix (Applied Biosystems) was used to prepare the PCR
mix. The ampliﬁcation reactions were carried out in the ABI Prism 7700
sequence detection system (Applied Biosystems) with initial hold steps (50°C
for 2 min, followed by 95°C for 10 min) and 50 cycles of a two-step PCR (92°C
for 15 s and 60°C for 1 min). The ﬂuorescence intensity of each sample was
measured at each temperature change to monitor ampliﬁcation of the target
gene. The comparative cycle time (CT) method was used to determine fold
differences between samples. The comparative CT method determines the
amount of target, normalized to an endogenous reference (glyceraldehyde-3-
phosphate dehydrogenase [GAPDH]) and relative to a calibrator (2
	

Ct).
Triglyceride determinations. Mouse hearts or H9C2 cells were homoge-
nized in 2  PBS. Tissue lipids were extracted with methanol:chloroform
(1:2), dried in an evaporating centrifuge and resuspended in 5% fat-free BSA.
Colorimetric assessment of cardiac and H9C2 cell triglyceride levels was
carried out using Sigma Diagnostics Triglyceride Reagent (Sigma Chemi-
cal, St. Louis, MO). Values were normalized to protein in homogenate
before extraction determined by the Bradford assay (Bio-Rad Laboratories,
Hercules, CA).
Western blotting assays. Western blotting assays were used to detect total
GSK-3, phosphorylated GSK-3 at Ser9, total glycogen synthase, phosphor-
ylated glycogen synthase at Ser641, PGC-1, and 3-nitrotyrocin (3-NT) (Cell
Signaling, Boston, MA); connective tissue growth factor (CTGF) (Chemicon,
Temecula, CA); and HK II, PPAR, and PAI-1 (BD Bioscience, Franklin Lakes,
NJ). Heart tissues were homogenized in lysis buffer using homogenizer. Tissue
or cell proteins were collected by centrifuging at 12,000g at 4°C in a Beckman
GS-6R centrifuge for 10 min. The protein concentration was measured by
Bradford assay. The sample, diluted in loading buffer and heated at 95°C for
5 min, was then subjected to electrophoresis on 10% SDS-PAGE gel at 120 V.
After electrophoresis of the gel and transfer of the proteins to nitrocellulose
membrane, the membranes were rinsed brieﬂy in tris-buffered saline, blocked
in blocking buffer (5% milk and 0.5% BSA) for 1 h, and washed three times with
tris-buffered saline containing 0.05% Tween 20. The membranes were incu-
bated with different primary antibodies at a dilution of 1:1,000 for 2 h and then
washed and reacted with secondary horseradish peroxidase–conjugated
antibody for 1 h. Antigen-antibody complexes were then visualized using ECL
kit (Amersham, Piscataway, NJ).
Sirius Red staining of collagen. Tissue sections of 5 m were used for
Sirius Red staining of collagen using 0.1% Sirius Red F3BA and 0.25% Fast
Green FCF. The sections stained for Sirius Red then were assessed for the
proportion of ﬁbrosis (collagen) using a computer-assisted image analysis
system as described in our previous study (4).
Statistical analysis. Data from repeated experiments were presented as
means  SD (n 6). One-way ANOVA, followed by post hoc multiple
comparisons tests with the Bonferroni test, was performed for the statistical
analysis. Differences were considered signiﬁcant at P  0.05.
RESULTS
Inactivation of GSK-3 in MT-TG mice is accompa-
nied by a signiﬁcant prevention of diabetes-induced
alterations in energy utilization–related molecules.
Wild-type and MT-TG diabetic mice showed similar, per-
sistent increases in whole-blood glucose levels until ex-
perimental termination 5 months after the onset of
diabetes induced by STZ (Fig. 1A). To test whether metal-
lothionein protects the heart from diabetes mediated by its
inactivation of GSK-3, the total expression and phosphor-
ylation of GSK-3 were examined from the hearts of the
wild-type and MT-TG diabetic mice at indicated times after
the onset of diabetes (Fig. 1B). We found that diabetes
induced a signiﬁcant decrease of GSK-3 phosphorylation
in the wild-type diabetic hearts—an effect that was not
observed in the MT-TG diabetic hearts.
Two major functions of GSK-3 are its negative regula-
tion of glucose metabolism and positive involvement in
apoptotic cell death pathway (9). We have demonstrated
the protection of metallothionein against diabetes-induced
cardiac cell death (22). In the following experiments,
therefore, we focus on effects of GSK-3 on energy me-
tabolism–related molecules and associated pathogenic
damages. Signiﬁcantly increased glycogen synthase phos-
phorylation was observed in the hearts of wild-type dia-
betic mice 2 and 5 months, but not 2 weeks, after diabetes
onset (Fig. 2A). Diabetes also signiﬁcantly decreased HK II
protein levels in the hearts of wild-type mice from 2 weeks
until 5 months (Fig. 2B). However, both altered glycogen
synthase phosphorylation and HK II abundance were
normalized in the MT-TG diabetic hearts (Fig. 2), suggest-
ing that glycogen synthesis and glucose metabolism de-
Control
C
Diabetes Control Diabetes
WT MT-TG
T
r
i
g
l
y
c
e
r
i
d
e
,
 
m
o
l
/
m
g
.
t
i
s
s
u
e
10
15
0
5
D
WT MT-TG
*
*, #
2 Ws
2 Ms
5 Ms
FIG. 3. Continued.
Y. WANG AND ASSOCIATES
DIABETES, VOL. 58, JUNE 2009 1395creased in the hearts of wild-type diabetic mice but not
MT-TG diabetic mice.
The decreased glucose metabolism in the wild-type
diabetic hearts was accompanied by increased cardiac
PPAR expression (Fig. 3A), a positive mediator for fatty
acid uptake and utilization. Furthermore, PGC-1 that acts
as an essential regulator for the maintenance of maximal
and efﬁcient cardiac mitochondrial fatty acid oxidation
was signiﬁcantly depressed in the wild-type diabetic hearts
but not in the MT-TG diabetic hearts (Fig. 3B). The
increased PPAR and decreased PGC-1 indicate the
imbalance of fatty acid metabolism. Consistent with this
notion, diabetes signiﬁcantly increased lipid accumulation
in the hearts of wild-type mice but not MT-TG mice from 2
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evidenced by Oil Red O staining (Fig. 3C) and biochemical
measurement of triglyceride levels (Fig. 3D).
Inactivation of GSK-3 in MT-TG mice prevents dia-
betes-induced pathogenic changes. We next deter-
mined whether altered glucose and lipid metabolisms are
accompanied by cardiac inﬂammation by detecting a few
inﬂammatory cytokines that were found to play critical
roles in the pathogenesis of diabetic cardiomyopathy
(23,24). Real-time RT-PCR analysis showed that TNF-
and ICAM-1 mRNA expression in the hearts of wild-type
diabetic mice was signiﬁcantly increased 2 weeks and 5
months (Fig. 4A) and 2 weeks and 2 months (Fig. 4B) after
diabetes, respectively. PAI-1 mRNA expression was signif-
icantly increased in the hearts of wild-type diabetic mice
from 2 weeks to 5 months after diabetes (Fig. 4C). In
addition, the increased PAI-1 expression in the hearts of
wild-type diabetic mice was further conﬁrmed by Western
blot analysis (Fig. 4D) and immunohistochemical localiza-
tion (Fig. 4E). However, the induction of inﬂammatory
cytokine expression was not observed in the hearts of
MT-TG diabetic mice.
The causative effect of cardiac lipid accumulation (ste-
atosis) on inﬂammation and oxidative damage has been
previously established (14,23–25). In line with this notion,
we also provided in vitro evidence that direct exposure of
cultured cardiac H9c2 cells to TNF- at a ﬁnal concentra-
tion of 1.0 ng/ml for 24 h did not increase triglyceride
levels (Fig. 5A). In contrast, direct exposure of cardiac
cells to free fatty acid (FFA) (palmitate at 50 mol) for
24 h not only signiﬁcantly increased intracellular triglyc-
eride levels (Fig. 5A) but also signiﬁcantly increased
mRNA expression of inﬂammatory cytokines TNF- and
PAI-1 (Fig. 5B and C).
Cardiac lipid accumulation and associated inﬂammation
were accompanied by signiﬁcant cardiac nitrosative dam-
age, examined by Western blotting assay for 3-NT as an
index of nitrosative damage in the wild-type diabetic
mice—an effect not observed in the MT-TG diabetic mice
(Fig. 6A). In addition, because the proinﬂammatory cyto-
kine PAI-1 is also proﬁbrotic given its inhibition of the
conversion of plasminogen to plasmin, we next examined
the diabetic effect on cardiac ﬁbrosis. As shown in Fig. 6,
diabetes increased cardiac CTGF expression (Fig. 6B) and
collagen deposition (evidenced by Sirius Red staining)
(Fig. 6C) in the wild-type, but not MT-TG, mice.
Pharmacological inactivation of GSK-3 completely
prevents diabetes-induced cardiac energy metabo-
lism changes, inﬂammation, and ﬁbrosis. The above
results indicate that inactivation of GSK-3 by metallothio-
nein in the MT-TG diabetic mice seems to lead to the
prevention of diabetes-induced cardiac energy metabolism
derangement, lipid accumulation, inﬂammation, oxidative
damage, and remodeling. To deﬁne whether the activation
of GSK-3 by its dephosphorylation is directly related to
diabetes-induced pathogenic effects, GSK-3–speciﬁc in-
hibitor SB216763 was given to the wild-type diabetic mice
at 600 g/kg body wt every other day for 2 months
immediately after the onset of diabetes. Inhibition of
GSK-3 activity completely prevented diabetes-induced
glycogen synthase phosphorylation (Fig. 7A), HK II down-
regulation (Fig. 7B), PPAR upregulation (Fig. 7C), PGC-1
downregulation (Fig. 7D), and lipid accumulation (Fig. 7E)
in the heart of the wild-type diabetic mice.
Inhibition of GSK-3 activity also signiﬁcantly prevented
diabetes-increased cardiac PAI-1 mRNA (Fig. 8A) and
protein expression (Fig. 8B) and 3-NT accumulation (Fig.
8C) and ﬁbrosis (Fig. 8D and E). This study ensures that
GSK-3 activation plays a critical role in diabetes-induced
cardiac glucose and lipid metabolism changes, inﬂamma-
tion, and ﬁbrosis.
DISCUSSION
The present study investigated the critical role of diabetic
activation of GSK-3 in the alteration of cardiac energy
metabolism, lipotoxicity, inﬂammation, nitrosative dam-
age, and remodeling and reveals the following innovative
ﬁndings. First, metallothionein preservation of GSK-3
phosphorylation in the heart resulted in a signiﬁcant
prevention of diabetic metabolic derangements, i.e., de-
creased glucose metabolism–related mediators (glycogen
synthase inactivation and HK II downregulation) and
increased lipid metabolism–related mediators (PPAR up-
regulation, PGC-1 downregulation, and lipid accumula-
tion). Second, metallothionein prevention of the metabolic
derangements was accompanied by a signiﬁcant preven-
tion of cardiac inﬂammation, nitrosative damage, and
remodeling (ﬁbrosis). Third, the association of metallo-
thionein inactivation of GSK-3 with its prevention of
diabetic energy derangement, lipid accumulation, inﬂam-
mation, and remodeling was ensured by the ﬁndings of the
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TNF- (B) and PAI-1 (C). *P < 0.05 vs. control.
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vation of GSK-3 plays a critical role in the pathogenesis
of diabetic cardiomyopathy.
Impaired regulation of glucose utilization is a main
feature in the heart of both type 1 and type 2 diabetes (26).
GSK-3 was originally identiﬁed as a regulator of glycogen
synthase, a rate-limiting enzyme that promotes glycogen
deposition. In the absence of insulin, active GSK-3 phos-
phorylates the serine residues in the COOH-terminal do-
main of glycogen synthase and negatively regulates its
activity, reducing the capacity of cells to synthesize and
store glycogen. Expression and activity of GSK-3 are
signiﬁcantly increased in the brain of mice with STZ-
induced diabetes (27,28) and in skeletal muscle samples
from humans with type 2 diabetes (29). Consistent with
previous studies (13,14), our study showed the signiﬁcant
activation of GSK-3 in the hearts of diabetic mice from 2
weeks to 5 months. Inhibition of GSK-3 by various ap-
proaches resulted in an activation of glycogen synthase
that increases rates of glycogen synthesis and offers
cardiac protection (15,27,28,30). However, it remains un-
clear whether and how inactivation of GSK-3 results in
cardiac protection against diabetes.
PPARs play important roles in metabolic homeostasis
and protection from a variety of stress-induced damages;
however, each member of the PPAR family (PPAR,- /,
and -) has a distinct role in different tissues under various
conditions (31). For instance, activation of both PPAR
and PPAR attenuated diabetic kidney disease in the
apolipoprotein E knockout mouse (32). Interestingly,
PPAR may potentially damage the heart (33) but is
essential in protecting cardiomyocytes from oxidative
damage (34). Cardiac PPAR transgenic mice showed
excessive FFA oxidation, lipid accumulation, reduced
glucose utilization, and cardiomyopathy—a phenotype
that is remarkably similar to the diabetic heart (7,35). In
contrast to PPAR, cardiac PPAR/ transgenic mice had
increased myocardial glucose utilization, did not accumu-
late myocardial lipid, and had normal cardiac function
(16). Furthermore, different roles of PPAR in the liver
and brain also have been noted recently (36). Therefore,
the roles of PPARs in metabolic homeostasis, anti-inﬂam-
mation, and cytotoxic protection are distinct in different
tissues under different conditions. In general, however,
PPAR expressions and activity are elevated in diabetes
and reduced in both cardiac ischemia and hypertrophy
(7,31,35).
The different roles of these PPARs may be related to the
expression of their comediators, such as the expressions
of PGC-1 under certain conditions (37). PGC-1 is essen-
tial for the maintenance of maximal, efﬁcient cardiac
mitochondrial fatty acid oxidation, ATP synthesis, and
lipid homeostasis (17). Under normal condition, PGC-1
expression in the liver is relatively low compared with that
in other tissues such as heart and brain that rely mainly on
aerobic metabolism for ATP production (17,37). Expres-
sion of PGC-1 in the liver increased in the animals with
fasting, insulin resistance, and diabetes (37); in contrast,
PGC-1 expression decreased in the heart of insulin-
resistant mice (5), in skeletal muscles of type 2 diabetic
patients (38), and in blood vessel media of STZ-injected
diabetic rats (39).
In the present study, the innovative ﬁnding is the
restoration of diabetic inhibition of HK II by inactivation of
GSK-3 in MT-TG diabetic mice (Fig. 1) or its speciﬁc
inhibitor (Fig. 7). To our knowledge, this is the ﬁrst report
demonstrating that HK II is negatively regulated by
GSK-3 in the heart. This was an in vitro study in which
chronic inhibition of GSK-3 protected against rotenone-
induced apoptosis in cultured neuronal cells as a result of
an enhancement of HK II–dependent glycolysis (40).
We also provide evidence that inhibition of diabetic
activation of GSK-3 either by metallothionein in MT-TG
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signiﬁcantly attenuated diabetic upregulation of PPAR
expression and downregulation of PGC-1 expression,
respectively (Fig. 6). To date, there has been no previous
study showing the direct link between GSK-3 and
PPAR, but there were two studies showing that upregu-
lation of Akt can signiﬁcantly downregulate PPAR ex-
pression (41,42), suggesting that PPAR expression is
regulated positively by GSK-3 and negatively by Akt.
Whether the Akt’s negatively regulated expression of
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remains to be further investigated. The ﬁnding of the
inhibition of PGC-1 expression by inactivating GSK-3 is
in line with results from other previous studies demon-
strating that GSK-3 reduces PGC-1 expression by stim-
ulating its proteasomal degradation (43). The present
study provides evidence that diabetic activation of GSK-3
plays a critical role in cardiac pathological changes.
Therefore, we propose a mechanism, as illustrated in
Fig. 8E. Impaired insulin signaling in the heart of both type
1 and type 2 diabetic subjects (13,14,26) depresses Akt-
dependent GSK-3 phosphorylation (Fig. 1), which alters
energy metabolism, leading to lipid accumulation (Figs. 2
and 3). The lipotoxic effects in the heart evoke the cardiac
inﬂammation, oxidative/nitrosative damage, remodeling
(Figs. 4–6), and eventual cardiac dysfunction (2,22). The
proposed mechanism is based on the following evidence.
First, cardiac lipid accumulation in the wild-type diabetic
mice was accompanied by increased cardiac inﬂammation
(Fig. 4) and nitrosative damage (Fig. 6A), and inhibition of
cardiac lipid accumulation by inactivation of GSK-3 (Fig.
7) is accompanied by prevention of cardiac inﬂammation
and nitrosative damage (Fig. 8). Second, in an in vitro
study, we found that exposure of cardiac cells to inﬂam-
matory factor TNF- did not increase triglyceride levels
(Fig. 5A) but that exposure to fatty acid signiﬁcantly
increased the inﬂammatory factors TNF- and PAI-1
mRNA expression (Fig. 5B and C). Third, mice with
cardiac-restricted overexpression of PPAR that enhances
cardiac fatty acid uptake and lipid accumulation and also
represses glucose metabolic genes showed a typical dia-
betic cardiomyopathy (7). The diabetic cardiomyopathy in
this model can be rescued by deletion of the long-chain
fatty acid transporter CD36 (35), suggesting the critical
role of increased lipid metabolisms and lipotoxicity in the
diabetic cardiomyopathy. Lastly, recent studies demon-
strated the prevention of diabetic cardiomyopathy by
inhibition of inﬂammation (23,24,44), suggesting that in-
ﬂammation may be a consequence of cardiac lipid accu-
mulation and toxicity. In support of this notion, ad-
ministration of mycophenolate mofetil that speciﬁcally
inhibited renal inﬂammation, but did not affect renal lipid
accumulation, signiﬁcantly prevented diabetic nephropa-
thy (25). Atorvastatin reduced diabetes-induced cardiac
inﬂammation and ﬁbrosis, resulting in improved left ven-
tricle function in the absence of LDL cholesterol lowering,
also suggesting that the cardiac inﬂammation under dia-
betic condition is a downstream, important mediator in
diabetic lipotoxicity and remodeling (44).
The last signiﬁcant ﬁnding from our study is that metal-
lothionein attenuated diabetes-induced GSK-3 activation,
leading to the restoration of a diabetic switch from glucose
to FFA metabolism in the heart that, in turn, causes the
subsequent pathological changes, illustrated in Fig. 8F.
Although it remains unclear how exactly metallothionein
inhibits GSK-3 activation, a possible preservation of Akt
expression and activation as upstream mediator of GSK-3
(Fig. 8F) may be an explanation. Diabetes suppresses Akt
expression and activation, and a few studies showed that
metallothionein protective effects are mediated by stimu-
lating Akt signaling (3,5). Nonetheless, an investigation
into the exact mechanism responsible is warranted in the
future study.
In summary, by using the MT-TG mouse model and
pharmacological inhibitor, the present study provides ev-
idence for the ﬁrst time that activation of GSK-3 plays a
pivotal role in diabetes-induced energy metabolic derange-
ment and, consequently, pathological remodeling in the
heart. There is a clinical potential of the present study
because zinc deﬁciency often occurs in diabetic patients
and also increases the prevalence of cardiac dysfunction
in diabetic patients (45). Upregulation of cardiac metallo-
thionein in diabetic mice by zinc supplementation sig-
niﬁcantly prevented the development of diabetic car-
diomyopathy (21). Diabetic patients treated with zinc also
had reduced risk of vascular diseases such as nephropa-
thy, retinopathy, and neuropathy (46,47). Therefore, the
studies underlying the mechanisms by which metallothio-
nein protects the diabetic heart will encourage develop-
ment of a metallothionein inducer of potential clinical use
for diabetic patients.
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